SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This investigator initiated pilot study is designed to investigate the efficacy and safety of
SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to
myopia. Newly diagnosed and active CNVs due to myopia are treated with one intravitreal
injection of Ranibizumab 0.5mg (Lucentis) at baseline. During the follow up period of 12
months monthly ophthalmological examinations including best corrected visual acuity (BCVA)
and high resolution spectral-domain optical coherence tomography (SD-OCT) assessments are
performed. Detection of persisting or new signs of CNV activity at OCT triggers ranibizumab
re-treatment considering that any ranibizumab injections can maximally be applied as often as
monthly.